From Early Champions to Established Care Pathways: Expanding Barostim Access Through Referrer Networks

Barostim™ benefits HF patients who remain symptomatic despite maximally tolerated guideline-directed medical therapy, including medications and devices. Like other novel therapies, early adoption can be slowed by care silos and uncertainty about where the therapy fits in the care continuum. Drawing on real-world implementation experience from two established Barostim programs that progressed from champion-led adoption to broader referrer networks, this CV business white paper outlines practical strategies to expand appropriate therapy access by gaining support from upstream providers and establishing well-defined workflows. 

ACCESS CV BUSINESS WHITE PAPER